期刊文献+

慢性肾脏病患者血清1,25(OH)_2D水平与蛋白尿及尿炎症细胞因子相关性研究 被引量:11

Correlation Between Serum 1,25(OH)_2D and Urinary Inflammatory Cytokines and Albuminuria in Chronic Kidney Disease Patients
暂未订购
导出
摘要 目的:探讨慢性肾脏病(CKD)1~4期患者血清1,25(OH)2D水平与蛋白尿、尿炎症细胞因子的关系。方法:对我科115例CKD1~4期患者及20例健康对照者进行血清1,25(OH)2D、血CRP,尿TGF-β1、MCP-1、TNF、IL-6,24h尿蛋白定量检测;分析血清1,25(OH)2D水平与以上指标相关性。结果:(1)CKD组患者血清1,25(OH)2D水平低于对照组(P<0.05);血CRP,尿MCP-1、TGF-β1、IL-6、TNF水平,24h尿蛋白定量高于对照组(P<0.05)。(2)与GFR≥60ml.min-1.1.73m-2患者比较:GFR<44ml.min-1.1.73m-2患者CRP,尿MCP-1、TGF-β1、IL-6、TNF水平、24h尿蛋白定量升高(P<0.05);血清1,25(OH)2D水平降低(P<0.05);而GFR45~59ml.min-1.1.73m-2患者与GFR≥60ml.min-1.1.73m-2患者比较,两组间差异无统计学意义(P>0.05);(3)单因素相关分析显示CKD患者血清1,25(OH)2D与年龄(r=-0.442)、收缩压(r=-0.464)、舒张压(r=-0.399)、GFR(r=0.902)、Scr(r=-0.430)、PTH(r=-0.341)、UA(r=0.237)、24h尿蛋白定量(r=-0.372)及尿TGF-β1(r=-0.894)、MCP-1(r=-0867)、TNF(r=-0.899)、IL-6(r=-0.934)水平相关(P<0.05)。多元回归分析显示血清1,25(OH)2D与GFR呈正相关;与24h尿蛋白定量,尿MCP-1、IL-6,血Scr、PTH呈负相关。结论:CKD1~4期患者存在1,25(OH)2D水平降低,并与蛋白尿及尿炎症细胞因子水平密切相关。 Objective:To study the relationship between serum 1,25(OH)2D levels and albuminuria and urinary inflammatory cytokines in chronic kidney disease(CKD)patients.Methods:Clinical and laboratory data of 115 hospitalized CKD patients and 20 healthy hospital staff as control group were collected.serum 1,25(OH)2D,urinary TGF-β1,MCP-1,TNF,IL-6 levels and the relationship between serum 1,25(OH)2D and these clinical parameters were analysed.Results:(1)The mean levels of,blood pressure,BUN,Scr,serum phosphorus,PTH,24h urinary protein,CRP,TC,TG,LDL,UA,urinary MCP-1,urinary TGF-β1,urinary IL-6,urinary TNF of CKD patients were higher than that of control group,and the mean levels of GFR,serum calcium,HDL,serum 1,25(OH)2D levels were lower than control group(P〈0.05).(2)Compared with patients of GFR ≥60 ml·min^-1·1.73 m^-2,Serum CRP,The mean levels of urinary TGF-β1,MCP-1,IL-6,TNF and 24 h urinary protein of patients with GFR44 ml·min^-1·1.73 m^-2,were higher(P〈0.05),serum 1,25(OH)2D was decreased(P〈0.05),but those difference were not significantly between patients with GFR ≥60 ml·min^-1·1.73 m^-2 and 45-59 ml·min^-1·1.73 m^-2(P〈0.05).(3)The levels of serum 1,25(OH)2D of CKD patients were related with age(r=-0.442),systolic blood pressure(r=-0.464),diastolic blood pressure(r =-0.399),GFR(r=0.902),Scr(r=-0.430),PTH(r=-0.341),UA(r=0.237),24 h urinary protein(r=-0.372)and urinary TGF-β1(r=-0.894),MCP-1(r =-0867),TNF(r=-0.899),IL-6(r=-0.934)(P〈0.05).(4)The levels of serum 1,25(OH)2D of CKD patients were positively correlated with GFR and negative correlated with PTH and 24 h urinary protein urinary TGF-β1,MCP-1,TNF,IL-6.Conclusion:The levels of serum 1,25(OH)2D of CKD patients were closely correlated with proteinuria and the levels of urinary inflammatory cytokines.
机构地区 解放军第
出处 《中国中西医结合肾病杂志》 2011年第4期311-314,共4页 Chinese Journal of Integrated Traditional and Western Nephrology
关键词 活性维生素D 慢性肾脏病 蛋白尿 尿炎症细胞因子 Vitamin D Kidney disease Proteinuria Inflammatory factors
  • 相关文献

参考文献17

  • 1Nagpal S,Na S,Rathnachalam R.Noncalcemic actions of vitamin D receptor ligands.Endocr Rev,2005,26(5):662-687.
  • 2Stubbs JR,Idicalla A,Slusser J,et al.Cholecalciferol supplementation alters calcitrio-responsive monocyte proteins and decreases inflammatory cytokines in ESRD.J Am Soc Nephrol,2010,21(2):353-361.
  • 3National Kidney Foundation.K/DOQI clinical practice guidelines for chronic kidney disease:eification,and stratification.Am J Kidney Dis,2002,39(suppl 1):S1-S266.
  • 4全国eGFR课题协作组.MDRD方程在我国慢性肾脏病患者中的改良和评估[J].中华肾脏病杂志,2006,22(10):589-595. 被引量:728
  • 5Ishimura E,Nishizawa Y,Inaba M,et al.Serum level of 1,25-dihydroxyvitamin D,24,25,-dihydroxyvitamin D,and 25,-hydroxyvitamin D in nondialyzed patients with chronic renal failure.Kidney Int,1999,55(3):1019-1027.
  • 6Levin A,Bakris GL.Prevalence of abnormal serum vitamin D,PTH,calcium,and phosphorus in patients with chronic kidney disease:results of the study to evaluate early kidney disease.Kidney Int,2007,71(1):31-38.
  • 7吕轶伦,林颍,史浩,张文,任红,陈楠.慢性肾脏病患者维生素D不足与缺乏[J].中华肾脏病杂志,2009,25(9):668-672. 被引量:34
  • 8Shoben AB,Rudser KD,de Boer ZH,et al.Association of oral Calcitriol with improved survival in nondialyzed CKD.J Am Soc Nephrol,2008,19(8):1613-1619.
  • 9娄探奇.CKD患者活性维生素应用.中华肾脏病学年会专题汇编,2010.133-135.
  • 10Fishbane S,Chittineni H,Packman M,et al.Oral paricalcitol in the treatment of patients with CKD and protinuria:a randomized trial.Am Jou Kid Dis,2009,54(4):647-652.

二级参考文献33

  • 1<活性维生素D的合理应用>专家协作组.活性维生素D在慢性肾脏病继发性甲旁亢中合理应用的专家共识(修订版)[J].中华肾脏病杂志,2005,21(11):698-699. 被引量:97
  • 2K/DOQI cllnical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis, 2003, 42: S1-S201.
  • 3Holick MF. Vitamin D deficiency. N Engl J Med, 2007, 357: 266-281.
  • 4Chonchol M, Scragg R. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney lnt, 2007, 71: 134-139.
  • 5Gonzalez EA, Sachdeva A, Oliver DA, et al. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol, 2004, 24: 503-510.
  • 6Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int, 2007, 71: 31-38.
  • 7Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med, 1998, 338: 777-783.
  • 8Saha H. Calcium and vitamin D homeostasis in patients with heavy proteinuria. Clin Nephrol, 1994, 41: 290-296.
  • 9Nykjaer A, Dragun D, Walther D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(0H) vitamin D3. Cell, 1999, 96: 507-515.
  • 10Forman JP, Giovannucci E, Holmes MD, et al. Plasma 25- hydroxyvitamin D levels and risk of incident hypertension. Hypertension, 2007, 49: 1063-1069.

共引文献758

同被引文献108

  • 1王海燕.肾脏病学[M].北京:人民卫生出版社,2008:1948-1949.
  • 2Campbell R,Sangalli F,Perticucciet E,et al.Effects of combined ACE inhibitor and angiotensinⅡantagonist treatment in human chronic nephropathies.Kidney Int,2003,63(3):1094-1103.
  • 3Zhang Y,Kong J,Deb DK,et al.Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system.Am Soc Nephrol,2010,21(6):966-973.
  • 4Agarwal R,Acharya M,Tian J,et al.Antiproteinuri effect of oral paricalcitol in chronic kidney disease.Kidney Int,2005,68(6):2823-2828.
  • 5He W,Kang YS,Dai C,et al.Blockade of Wnt/β-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury.J Am Soc Nephrol,2011,22(1):90-103.
  • 6Zhou C,Lu F,Cao K,et al.Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-ang iotensin System in1alpha-hydroxylase knockout mice.Kidney Int,2008,74(2):170-179.
  • 7Dogan M,Erol M,Cesur Y,et al.The effect of 25-hydroxyvitamin D3 on the immune system.J Pediatr Endocrinol Matab,2009,22(10):929-935.
  • 8Ishimura E,Nishizawa Y,Inaba M,et al.Serum level of 1,25-dihydroxy vitamin D,24,25-dihydroxyvitamin D,and 25,-hydroxyvitamin D in nondialyzed patients with chronic renal failure[J].Kidney Int,1999,55(3):1019-1027.
  • 9Shoben A B,Rudser K D,de Boer Z H,et al.Association of oral Calcitriol with improved survival in nondialyzed CKD[J].J Am Soc Nephrol,2008,19(8):1613-1619.
  • 10de Boer IH,Ioannou GN, Kestenbaum B,et al. 25-hydroxyvitaminD levels and albuminuria in the Third National Health and Nutri-tion Examination Survey ( NHANES 皿)[J]. Am J Kidney Dis,2007,50(l):69-77.

引证文献11

二级引证文献81

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部